Literature DB >> 17396269

[Therapeutic standards for ovarian cancer].

J Pfisterer1, A du Bois.   

Abstract

Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate. Recently, numerous findings have emerged on the status and extent of surgical therapy for this disease. Innovations in the chemotherapy of primary and recurrent disease are also plentiful. It is essential for the improvement of the patients' situation to transfer these new developments, already integrated into national and international standards and guidelines, into clinical practice.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17396269     DOI： 10.1007/s00292-007-0907-9

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  15 in total

1.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.

Authors:  S M Eisenkop; R L Friedman; N M Spirtos
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

2.  Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

Authors:  M Markman; W Hoskins
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

3.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

5.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Angelo Maggioni; Neville Hacker; Fabio Landoni; Sven Ackermann; Elio Campagnutta; Karl Tamussino; Raimund Winter; Antonio Pellegrino; Stefano Greggi; Roberto Angioli; Natalina Manci; Giovanni Scambia; Tiziana Dell'Anna; Roldano Fossati; Irene Floriani; Rita S Rossi; Roberto Grassi; Giuseppe Favalli; Francesco Raspagliesi; Diana Giannarelli; Luca Martella; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2005-04-20       Impact factor: 13.506

6.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

Authors:  A du Bois; M Quinn; T Thigpen; J Vermorken; E Avall-Lundqvist; M Bookman; D Bowtell; M Brady; A Casado; A Cervantes; E Eisenhauer; M Friedlaender; K Fujiwara; S Grenman; J P Guastalla; P Harper; T Hogberg; S Kaye; H Kitchener; G Kristensen; R Mannel; W Meier; B Miller; J P Neijt; A Oza; R Ozols; M Parmar; S Pecorelli; J Pfisterer; A Poveda; D Provencher; E Pujade-Lauraine; M Randall; J Rochon; G Rustin; S Sagae; F Stehman; G Stuart; E Trimble; P Vasey; I Vergote; R Verheijen; U Wagner
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

7.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

8.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

Authors:  J Baptist Trimbos; Ignace Vergote; Giorgio Bolis; Jan B Vermorken; Constantino Mangioni; Caterina Madronal; Massimo Franchi; Saverio Tateo; Gerardo Zanetta; Giovanna Scarfone; Livia Giurgea; Petra Timmers; Corneel Coens; Sergio Pecorelli
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

9.  International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

Authors:  Nicoletta Colombo; David Guthrie; Stefania Chiari; Mahesh Parmar; Wendi Qian; Ann Marie Swart; Valter Torri; Christopher Williams; Andrea Lissoni; Cristina Bonazzi
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

10.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
View more
  1 in total

1.  Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.

Authors:  Matthias Choschzick; Egbert Oosterwijk; Volkmar Müller; Linn Woelber; Ronald Simon; Holger Moch; Pierre Tennstedt
Journal:  Virchows Arch       Date:  2011-06-21       Impact factor: 4.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.